厄他培南在治疗培养结果为阳性的复杂性腹腔内感染中的作用
The Role of Ertapenem for the Treatment of Complicated Intra-abdominal Infections With a Positive Culture for .
作者信息
Fabre Valeria, Nemati Koorosh, Avdic Edina, Cosgrove Sara E, Amoah Joe, Tamma Pranita D
机构信息
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
出版信息
Open Forum Infect Dis. 2018 Dec 15;6(1):ofy339. doi: 10.1093/ofid/ofy339. eCollection 2019 Jan.
Abstract
Controversy remains as to whether recovered from intra-abdominal infections (IAIs) requires targeted therapy. In a multicenter study comparing patients with IAIs from which was identified in intra-abdominal cultures, no difference in clinical outcomes was observed between patients receiving ertapenem vs those receiving piperacillin/tazobactam.
摘要
对于从腹腔内感染（IAIs）中康复的患者是否需要靶向治疗仍存在争议。在一项多中心研究中，比较了腹腔内培养物中鉴定出[病原体]的IAIs患者，接受厄他培南治疗的患者与接受哌拉西林/他唑巴坦治疗的患者在临床结局上未观察到差异。
相似文献
1
The Role of Ertapenem for the Treatment of Complicated Intra-abdominal Infections With a Positive Culture for .厄他培南在治疗培养结果为阳性的复杂性腹腔内感染中的作用
Open Forum Infect Dis. 2018 Dec 15;6(1):ofy339. doi: 10.1093/ofid/ofy339. eCollection 2019 Jan.
2
Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.动态微生物环境对厄他培南和哌拉西林/他唑巴坦治疗西班牙复杂社区获得性腹腔内感染临床疗效的影响：一项成本-后果分析
Appl Health Econ Health Policy. 2015 Aug;13(4):369-79. doi: 10.1007/s40258-015-0162-9.
3
Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.体重指数对住院成人复杂腹腔内感染治疗的影响：厄他培南与哌拉西林-他唑巴坦的比较。
Surg Infect (Larchmt). 2012 Feb;13(1):38-42. doi: 10.1089/sur.2010.095. Epub 2012 Jan 4.
4
Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.厄他培南静脉注射与哌拉西林/他唑巴坦治疗住院成人复杂性腹腔内感染的疗效、安全性和耐受性的随机、多中心、双盲研究
Surg Infect (Larchmt). 2007 Feb;8(1):15-28. doi: 10.1089/sur.2006.030.
5
Bactericidal activity of ertapenem against major intra-abdominal pathogens.厄他培南对主要腹腔内病原体的杀菌活性。
Int J Antimicrob Agents. 2006 Nov;28(5):396-401. doi: 10.1016/j.ijantimicag.2006.07.018. Epub 2006 Oct 11.
6
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.厄他培南与哌拉西林-他唑巴坦治疗混合性厌氧性复杂性腹腔内感染、复杂性皮肤及皮肤结构感染和急性盆腔感染的比较
Surg Infect (Larchmt). 2002 Winter;3(4):303-14. doi: 10.1089/109629602762539535.
7
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.在一项针对腹腔内感染的厄他培南与哌拉西林-他唑巴坦治疗的双盲随机临床试验期间获得耐药肠道菌群。
Antimicrob Agents Chemother. 2005 Aug;49(8):3217-21. doi: 10.1128/AAC.49.8.3217-3221.2005.
8
Does Isolation of Enterococcus Affect Outcomes in Intra-Abdominal Infections?分离肠球菌是否会影响腹腔内感染的预后？
Surg Infect (Larchmt). 2017 Nov/Dec;18(8):879-885. doi: 10.1089/sur.2017.121. Epub 2017 Oct 10.
9
Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam.厄他培南或哌拉西林他唑巴坦治疗复杂性尿路感染的疗效和再感染率。
Turk J Med Sci. 2016 Dec 20;46(6):1760-1764. doi: 10.3906/sag-1506-157.
10
Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.肠球菌引起的外科感染：厄他培南与哌拉西林-他唑巴坦治疗患者的结局
Surg Infect (Larchmt). 2002 Winter;3(4):337-49. doi: 10.1089/109629602762539553.
引用本文的文献
1
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use.腹腔内感染的管理：意大利抗菌药物优化使用理事会的建议。
World J Emerg Surg. 2024 Jun 8;19(1):23. doi: 10.1186/s13017-024-00551-w.
2
Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an Pharmacodynamic Model Using Humanized Dosing Simulations.美罗培南联合头孢洛林在使用人群剂量模拟的药效动力学模型中对粪肠球菌有效。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0042622. doi: 10.1128/aac.00426-22. Epub 2022 Sep 26.
本文引用的文献
1
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection.外科感染学会关于腹腔内感染管理的修订指南。
Surg Infect (Larchmt). 2017 Jan;18(1):1-76. doi: 10.1089/sur.2016.261.
2
Trial of short-course antimicrobial therapy for intraabdominal infection.腹腔内感染短程抗菌治疗试验
N Engl J Med. 2015 May 21;372(21):1996-2005. doi: 10.1056/NEJMoa1411162.
3
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.成人和儿童复杂性腹腔内感染的诊断和治疗：外科感染学会和美国传染病学会的指南。
Surg Infect (Larchmt). 2010 Feb;11(1):79-109. doi: 10.1089/sur.2009.9930.
4
Intra-abdominal infections: etiology, epidemiology, microbiological diagnosis and antibiotic resistance.腹腔内感染：病因、流行病学、微生物学诊断及抗生素耐药性
J Chemother. 2009 Jul;21 Suppl 1:5-11. doi: 10.1179/joc.2009.21.Supplement-1.5.
5
Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.厄他培南静脉注射与哌拉西林/他唑巴坦治疗住院成人复杂性腹腔内感染的疗效、安全性和耐受性的随机、多中心、双盲研究
Surg Infect (Larchmt). 2007 Feb;8(1):15-28. doi: 10.1089/sur.2006.030.
6
Bactericidal activity of ertapenem against major intra-abdominal pathogens.厄他培南对主要腹腔内病原体的杀菌活性。
Int J Antimicrob Agents. 2006 Nov;28(5):396-401. doi: 10.1016/j.ijantimicag.2006.07.018. Epub 2006 Oct 11.
7
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.厄他培南与哌拉西林-他唑巴坦治疗需要手术干预的腹腔内感染的疗效与安全性比较
J Gastrointest Surg. 2006 Apr;10(4):567-74. doi: 10.1016/j.gassur.2005.06.015.
8
Properties and potential of ertapenem.厄他培南的特性与潜力。
J Antimicrob Chemother. 2003 Sep;52(3):331-44. doi: 10.1093/jac/dkg375. Epub 2003 Aug 13.
9
Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.肠球菌引起的外科感染：厄他培南与哌拉西林-他唑巴坦治疗患者的结局
Surg Infect (Larchmt). 2002 Winter;3(4):337-49. doi: 10.1089/109629602762539553.
10
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.厄他培南与哌拉西林/他唑巴坦治疗复杂性腹腔内感染：一项双盲、随机对照III期试验的结果
Ann Surg. 2003 Feb;237(2):235-45. doi: 10.1097/01.SLA.0000048551.32606.73.
Zotero 插件